Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 765423 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

Boehringer Ingelheim1 site in 1 country64 target enrollmentJanuary 16, 2023

ConditionsHealthy

InterventionsBI 765423 Placebo

DrugsBI 765423 Placebo

Overview

Phase: Phase 1
Intervention: BI 765423
Conditions: Healthy
Sponsor: Boehringer Ingelheim
Enrollment: 64
Locations: 1
Primary Endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765423 in healthy male subjects following intravenous administration of single rising doses.

Registry

clinicaltrials.gov

Start Date

January 16, 2023

End Date

March 19, 2024

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Male

Investigators

Sponsor

Boehringer Ingelheim

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
•Age of 18 to 55 years (inclusive)
•Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
•Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
•Male subjects who are willing to use condoms to prevent unintended exposure of their partner (both, male and female) from time point of administration of trial medication until completion of the trial. Male subjects with female partners must meet one of the following criteria for a highly effective contraception from at least screening until at least end-of-trial visit:
•Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal or transdermal) by female Women of child-bearing potential (WOCBP) partner, plus condom in male subject
•Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants) by female WOCBP partner, plus condom in male subject
•Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) by female WOCBP partner, plus condom in male subject
•Male subject is vasectomised (vasectomy at least 1 year prior to enrolment) and received medical assessment of the surgical success (documented absence of sperm), plus condom in male subject
•Female partner is surgically sterilised (including hysterectomy), plus condom in male subject

Exclusion Criteria

•Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
•Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)(subjects with heart rate values between 45 and 50 bpm may be enrolled in case they have a normal thyroid function, no clinical symptoms associated with the bradycardia and no apparent signs of other diseases causing bradycardia such as hypothyroidism)
•Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
•Any evidence of a concomitant disease assessed as clinically relevant by the investigator
•Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
•Major surgery (major according to the investigator's assessment) performed within 3 months prior to screening or planned after screening during the study, e.g. hip replacement
•Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
•History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.

Arms & Interventions

BI 765423 treatment group

BI 765423

Intervention: BI 765423

Placebo group

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator

Time Frame: up to 183 days

Secondary Outcomes

Maximum measured concentration of the analyte in serum (Cmax)(up to 183 days)
Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)(up to 183 days)